Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Non-coding RNA for treating delayed healing of diabetic wounds and diabetes-related complications and application of non-coding RNA

A technology for wound healing and diabetes, which is applied in the field of drugs for the treatment of delayed wound healing in diabetes and diabetes-related complications, and in the field of nucleotide sequences for the treatment of delayed wound healing in diabetes and related complications of diabetes, which can solve the problems of less drugs and no treatment to promote wound healing

Inactive Publication Date: 2016-01-06
HARBIN MEDICAL UNIVERSITY
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At present, there is no effective method for the treatment of diabetic wounds and complications caused by diabetes, such as ulcers, erosions, and diabetic feet. The main methods are to reduce blood sugar and blood lipids, treat with antibiotics, and there are very few drugs that directly promote wound healing.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Non-coding RNA for treating delayed healing of diabetic wounds and diabetes-related complications and application of non-coding RNA
  • Non-coding RNA for treating delayed healing of diabetic wounds and diabetes-related complications and application of non-coding RNA
  • Non-coding RNA for treating delayed healing of diabetic wounds and diabetes-related complications and application of non-coding RNA

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1: The role of microRNA-23a in promoting wound healing in diabetic mice

[0034] 1. Preparation of diabetic mouse model

[0035] The process of preparing diabetic mice is as follows: purchase 20-22g Kunming male mice of SPF level, feed them to about 25-28g and fast for 16-18h, then intraperitoneally inject streptozotocin at a dose of 1.8mg / 10g, measure the mice after 7d Fasting blood glucose was screened.

[0036]The preparation process of streptozotocin solution is as follows: streptozotocin needs to be dissolved in sodium citrate buffer solution with a final concentration of 10 mg / ml, and stored at -4°C in the dark. Since the biological half-life of streptozotocin is very short, It needs to be prepared immediately, and injected quickly in a short period of time.

[0037] Sodium citrate buffer solution preparation: 2.1g citric acid was dissolved in 100ml sterile water for injection to make citric acid solution, 2.94g sodium citrate was dissolved in 100ml ster...

Embodiment 2

[0046] Example 2: Effect of microRNA-23a on proliferation of endothelial cells

[0047] 1. Method

[0048] The cell transfection process is as follows: human umbilical vein endothelial cells (HUVEC) were inoculated in a six-well plate, and when the cell density reached 60%-80%, Agomir-23a (preparation method was the same as in Example 1), antagomiR-23a ( Guangzhou Ruibo Biotechnology Co., Ltd.) and negative control (NC) powder (Guangzhou Ruibo Biotechnology Co., Ltd.) dissolved in ddH 2 O was added to a six-well plate at a concentration of 20nmol / l and placed in 5% CO at 37°C 2 The culture was incubated in an incubator, and the experiment was carried out after 48 hours.

[0049] agomiR-23a is an agonist of microRNA-23a. antagomiR-23a is an antagonist of microRNA-23a. NC is a negative control.

[0050] The MTT experiment process is as follows: digest and centrifuge the transfected cells of each group, inoculate 10,000 cells / well in a 96-well plate, and place them in 5% CO ...

Embodiment 3

[0053] Example 3: The effect of microRNA-23a on the migration ability of endothelial cells

[0054] 1. Method

[0055] The procedure of the scratch experiment was as follows: human umbilical vein endothelial cells transfected with agomiR-23a, antagomiR-23a and NC in the logarithmic growth phase were collected (the preparation and transfection methods were the same as in Example 2), and seeded in a six-well plate. When the cell density reaches 90%, treat with mitomycin C (2 μg / ml) for 2 hours, use a 200 μl pipette tip to draw a straight line scratch in each well with a sterile ruler, and wash three times with PBS. After 24 hours, the same scratch position was observed under an inverted microscope and photographed to record the cell migration.

[0056] Three fields of view were used for each well, and the cell migration distance was analyzed by Image-ProPlus software. Cell migration distance = scratch width at 0 hours - scratch width at 24 hours.

[0057] 2. Results

[0058]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses firstly non-coding RNA for treating delayed healing of diabetic wounds and diabetes-related complications and application of the non-coding RNA. Upon animal experiments, the non-coding RNA disclosed by the invention is proved to be effective on promoting healing of diabetic wounds, and the non-coding RNA is of great significance for the treatment of delayed healing of wounds in patients of diabetes and for the treatment of ulcer, erosion, gangrene and diabetic foot caused by the diabetes.

Description

technical field [0001] The invention relates to a medicine for treating delayed wound healing of diabetes and diabetes-related complications, in particular to a nucleotide sequence for treating delayed wound healing of diabetes and related complications of diabetes. The invention belongs to the technical field of biomedicine. Background technique [0002] Diabetes mellitus is a disease with metabolic disorder as the main clinical manifestation caused by high blood sugar and insufficient insulin secretion in the body. Statistics show that there are currently 285 million diabetics in the world, and it is predicted that by 2030 the number of diabetics in the world will reach 439 million. Diabetes has become the fourth leading cause of human death after cardiovascular, tumor and AIDS. [0003] Complications caused by diabetes have become the main cause of disability and death of patients. Among the many complications of diabetes, the impaired wound healing ability of diabetic ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61K31/7088A61P3/10A61P17/02
Inventor 杨宝峰吕延杰王志国白云龙杜智敏
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com